Key facts
- It has raised $14.6M.
- Notable investors include Arar Capital, Esalqtec, Mitsubishi, Nitro Química, Rise Ventures — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for Gênica
- ·The full record, as it builds
Funding rounds
No funding rounds for Gênica are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Gênica
Operator of an agriculture research company intended to develop a vaccine for a common soybean fungus. The company offers integrated pest and disease management technology aimed at controlling insects and phytopathogenic microorganisms and its services focus on the production of agricultural pesticides, enabling clients to receive protection for their crops from various sorts of fungal diseases using their chemical products.
- Sector
- Materials and Resources
- HQ
- Piracicaba, Brazil
- Founded
- 2015
- Employees
- 243
- Website
- genica.com.br/
- Ownership
- Privately Held (backing)
Gênica doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gênica shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gênica in its N-PORT filings yet. We sweep new filings monthly.